WCLC24 . El Fármaco Contra el Cáncer de Pulmón de SUMMIT THERAPEUTICS ( IVONESCIMAB ) Muestra un Beneficio " SORPRENDENTE " Sobre KEYTRUDA ( MERCK ) lo Que Indica un Posible Nuevo ESTÁNDAR en el CÁNCER DE PULMÓN .

 

Detailed Data Show Summit Therapy Beat Merck Blockbuster KEYTRUDA in Late-Stage Lung Cáncer Trial . The Drug Reduced The Risk Of Tumor Progression By 49% Compared To The STANDAR Of Care .

World Conference on Lung Cancer , September 8, 2024 .

The Summit Drug, an Antibody Called IVONESCIMAB, Reduced The Risk Of Tumor Progression By 49% Compared To KEYTRUDA, According To Data Released Here At The World Conference on Lung Cancer .

 At The Median, Patients Treated With IVONESCIMAB ( AK112 ) Went 11.1 Months Before Their Tumors Began To Grow Again Compared To 5.8 Months For Patients on KEYTRUDA .  ...